NCT05516329View on ClinicalTrials.gov

Study of 18F-Thretide PET/CT in Patients With Prostate Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

August 20, 2022

Primary Completion Date

March 31, 2023

Study Completion Date

September 1, 2023

Conditions
Prostate Cancer
Interventions
DRUG

A single dose of 7±1 mCi (259±37 MBq) IV injection of 18F-Thretide

The patients will be intravenously injected with 18F-Thretide and undergo PET/CT scan at 60\~120 min after the injection.

Trial Locations (1)

350005

Department of Nuclear Medicine, First Affiliated Hospital of Fujian Medical University, Fuzhou

All Listed Sponsors
lead

First Affiliated Hospital of Fujian Medical University

OTHER